Resiniferatoxin for detrusor instability refractory to anticholinergics.
OBJECTIVE
We have evaluated the clinical and urodynamic effects of intravesical instillation of resiniferatoxin in patients with idiopathic detrusor instability refractory to anticholinergics.


METHODS
There were 30 women, median age 56 years old with detrusor instability for over 6 months and a history of anticholinergic use with no response or intolerable collateral effects. A 50 nM solution of resiniferatoxin was prepared for intravesical instillation. All patients were evaluated for urinary symptoms, as well as for urodynamic assessments before and 30 days after instillation. Tolerability was analyzed during the instillation.


RESULTS
A clinical improvement was observed in 30% of the patients with urinary urgency and in 33% of the patients with urge-incontinence. The mean maximum cystometric capacity before application was 303.9 +/- 78.9 and after application 341 +/- 84.6. No significant difference was observed (p = 0.585). The mean maximum amplitude of the contractions diminished from 47.86 +/- 29.64 to 38.72 +/- 30.77 (p = 0.002).


CONCLUSIONS
Resiniferatoxin, in this concentration, proved to be useful in a small percentage of patients regarding clinical detrusor instability. Maximum amplitude of the involuntary contractions was significantly reduced and in 33% patients the involuntary contractions disappeared. Further studies with different concentrations are recommended.
Palma
Paulo C R
PC
Division of Urology, State University of Campinas, UNICAMP, Campinas, São Paulo, Brazil.
Thiel
Marcelo
M
Riccetto
Cássio L Z
CL
Dambros
Miriam
M
Miyaoka
Ricardo
R
Netto
N Rodrigues
NR
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018680:Cholinergic Antagonists / Q000494:pharmacology; D004224:Diterpenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008875:Middle Aged; D009122:Muscle Hypertonia; D009498:Neurotoxins; D016896:Treatment Outcome; D001745:Urinary Bladder Diseases / Q000150:complications / Q000188:drug therapy; D014549:Urinary Incontinence / Q000188:drug therapy / Q000209:etiology; D014555:Urination Disorders / Q000188:drug therapy*; D014563:Urodynamics
D018680:Cholinergic Antagonists; D004224:Diterpenes; D009498:Neurotoxins; C024353:resiniferatoxin